Logo Image
Business
Practice ManagementMalpractice ConsultHealth Law & Policy
Media
Case-Based Peer PerspectivesInvestigator Perspectives Medical World NewsPodcastsUrology Medical PerspectivesUTv VideosPeer ExchangeSpecial ReportVirtual Tumor BoardClinical Forum InsightsInsightsMedcastPeers & PerspectivesShorts
Conferences
Conference ListingConference Previews Conference Recaps
Publications
Urology Times JournalEditorial Advisory BoardUrologists in Cancer CareSupplements and Featured PublicationsClinical Forums Recaps
More
CME/CE
Resources
Begin Your Journey: Tackling BurnoutSponsored MediaLive EventsInteractive ToolsJob BoardPartnersSponsored ResourcesTreatment Landscape Evolutions

Subscribe

  • Business
  • Media
  • Conferences
  • Publications
  • CME/CE
  • Resources
  • Subscribe
  • Benign Conditions
  • Benign Prostatic Hyperplasia
  • Bladder Cancer
  • Female Urology
  • Genitourinary Cancers
  • Genomic Testing
  • Hormone Therapy
  • Kidney Cancer
  • Kidney Stones
    • Challenging Anatomy
  • Men's Health
  • Next-Generation Imaging
  • OAB and Incontinence
    • Voiding Dysfunction
  • Pediatrics
  • Prostate Cancer
    • Controveries in Urologic Cancer
    • Drug Therapy
  • Sexual Dysfunction
  • UTUC
  • Urologic Surgery
    • Cosmetic Surgery
Spotlight -
Peer Exchange|
Peers and Perspectives|
Case-Based Peer Perspectives|
Urology Times Journal
Advertisement

Martin G. Sanda, MD

Advertisement

Articles by Martin G. Sanda, MD

Prostate cancer treatments: Assessing effects on quality of life

ByAndrew A. Wagner, MD,Martin G. Sanda, MD
September 1st 2006

The most instructive HRQoL studies are those that rely on prospective, longitudinal assessments of patients using a validated instrument.

Advertisement

Latest Updated Articles

  • Prostate cancer treatments: Assessing effects on quality of life
    Prostate cancer treatments: Assessing effects on quality of life

    September 1st 2006



Advertisement
Advertisement

Trending on Urology Times

1

Published data show DFS benefit with aglatimagene besadenovec in localized prostate cancer

2

Study suggests potential diuretic effect with nadofaragene firadenovec

3

Nicole L. Miller, MD, FACS, on assessing patients after BPH treatment failure

4

The UroOnc Minute: MDT for Oligometastatic Prostate Cancer, with Chad Tang, MD

5

RAD-IO: Durvalumab plus chemoradiotherapy is feasible in MIBC

  • About Us
  • Advertise
  • Editorial
  • Contact Us
  • Job Board
  • Terms and Conditions
  • Privacy
  • Do not sell my Personnal Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

  • Contagion Live
  • CGT Live
  • Neurology Live
  • HCP Live
  • Oncology Live
  • Contemporary Pediatrics
  • Contemporary OBGYN
  • Urology Times
  • The Educated Patient
  • Patient Care Online
HCP Live Network
Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us